L30 CA123387-01/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Year	Number of Results
2009	1
2010	1
2011	2
2024	0

Page 1

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.

Gajria D, Chandarlapaty S. Gajria D, et al. Expert Rev Anticancer Ther. 2011 Feb;11(2):263-75. doi: 10.1586/era.10.226. Expert Rev Anticancer Ther. 2011. PMID: 21342044 Free PMC article. Review.

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth.

Chandarlapaty S, Scaltriti M, Angelini P, Ye Q, Guzman M, Hudis CA, Norton L, Solit DB, Arribas J, Baselga J, Rosen N. Chandarlapaty S, et al. Oncogene. 2010 Jan 21;29(3):325-34. doi: 10.1038/onc.2009.337. Epub 2009 Oct 26. Oncogene. 2010. PMID: 19855434 Free PMC article.

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer.

Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M, Rodriguez S, Gili M, Russillo M, Parra JL, Singh S, Arribas J, Rosen N, Baselga J. Serra V, et al. Oncogene. 2011 Jun 2;30(22):2547-57. doi: 10.1038/onc.2010.626. Epub 2011 Jan 31. Oncogene. 2011. PMID: 21278786 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year